GDNF releasing cells reduce epilepsy induced cell death. In a normal hippocampus (A) no overt sign of cell death can be observed, whereas many dying cells (stained in green) are observed in the epileptic hippocampus (B). GDNF releasing cells effectively attenuate cell death (C).
CREDIT
Giovanna Paolone
Implantable device curbs seizures and improves cognition in epileptic rats
A protein-secreting device implanted into the hippocampus of epileptic rats reduces seizures by 93 percent in three months, finds preclinical research published in JNeurosci. These results support ongoing development of this technology and its potential translation into a new treatment for epilepsy.
Motivated by an unmet need for effective and well-tolerated epilepsy therapies, Giovanna Paolone and colleagues of the University of Ferrara, Italy and of Gloriana Therapeutics, Inc. (Providence, RI) investigated the effects of the Gloriana targeted cellular delivery system for glial cell line-derived neurotrophic factor (GDNF) — a protein recent research suggests may help suppress epileptic activity.
In addition to quickly and progressively reducing seizures in male rats — by 75 percent within two weeks — the researchers found their device improved rats’ anxiety-like symptoms and their performance on an object recognition task, indicating improvement in cognition.
The treatment also corrected abnormalities in brain anatomy associated with epilepsy. These effects persisted even after the device was removed, indicating this approach may modify the disease progression.
Learn more: Implantable device curbs seizures and improves cognition in epileptic rats
The Latest on: Epilepsy treatment
via Google News
The Latest on: Epilepsy treatment
- As NY prepares for legal weed, U.S. must open doors for cannabis research | Opinionon January 12, 2021 at 9:25 am
But American researchers who want to study cannabis are thwarted at every turn. Federal law still classifies cannabis as a Schedule 1 drug, a list that includes highly dangerous and addictive drugs ...
- Neuraxpharm launches first product in Japanon January 12, 2021 at 12:14 am
Launch of Buccolam® - market leading product for emergency treatment of children with epilepsy suffering from prolonged acute convulsive ...
- Couple 'spend hundreds' on medicinal cannabis for one-year-old with epilepsyon January 11, 2021 at 8:51 am
A couple from Frome whose daughter has severe epilepsy have spent hundreds of pounds on medicinal cannabis because they cannot access it on the NHS. Emily Howis and Spencer Carkeet are now campaigning ...
- Epilepsy midwife looks at risks around epilepsy drugs during pregnancyon January 7, 2021 at 11:24 am
Epilepsy specialist midwife Kim Morley looks at what the latest review on risks associated with epilepsy drugs during pregnancy means for women. "The MHRA publication on epilepsy medications and ...
- Graybug Vision completes treatment phase of mid-stage ALTISSIMO trial in wet AMDon January 7, 2021 at 7:47 am
Clinical-stage biopharmaceutical company Graybug Vision (GRAY +0.9%) completes its GB-102 Phase 2b ALTISSIMO core trial ((the 12-month treatment phase)) in wet age-related macular degeneration ((wet ...
- A medical cannabis treatment saved my son’s life and Brexit means we can no longer access iton January 7, 2021 at 6:03 am
Alfie was first person in the UK to be issued with medical cannabis on the NHS - but now UK prescriptions cannot be dispensed in EU member states ...
- Parents of children with severe epilepsy warn cannabis medication stopping after Brexiton January 7, 2021 at 5:16 am
Tannine Clarry, 32, from Suffolk, fears that losing access to the prescription will cost her six-year-old daughter Indie-Rose her independence and set back years of progress.
- Parents of children with severe epilepsy urge government to intervene after Brexit stopped supply of 'life-saving' cannabis medication from the Netherlands - with supplies set ...on January 7, 2021 at 5:16 am
Tannine Clarry, 32, from Suffolk, fears that losing access to the prescription will cost her six-year-old daughter Indie-Rose her independence and set back years of progress.
- Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations for Severe Pediatric Epilepsy Programson January 7, 2021 at 5:15 am
As a company deeply rooted in the genetic drivers of severe pediatric epilepsies, these designations are especially meaningful and validating,” said Marcio Souza, president and chief executive officer ...
- Avicanna Advances Pharmaceutical Epilepsy Program With Collaboration With the University Health ...on January 6, 2021 at 4:32 am
The multi-level cannabinoid-based collaboration with leading epilepsy researcher Dr. Peter Carlen at the world-renowned Krembil Research Institute at UHN is also supported by a Mitacs Accelerate ...
via Bing News
